Abetimus

Drug Profile

Abetimus

Alternative Names: Abetimus sodium; LJP 394; Riquent

Latest Information Update: 16 Feb 2009

Price : $50

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Oligonucleotides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Lupus nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lupus nephritis

Most Recent Events

  • 12 Feb 2009 Discontinued - Phase-III for Lupus nephritis in India (IV)
  • 12 Feb 2009 Discontinued - Phase-III for Lupus nephritis in Eastern Europe (IV)
  • 12 Feb 2009 Discontinued - Phase-III for Lupus nephritis in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top